Pdt Partners, LLC Collegium Pharmaceutical, Inc Transaction History

Pdt Partners, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$16.14 - $23.55 $169,405 - $247,180	-10,496 Reduced 28.91%	25,804 $598,000
Q3 2022 Nov 14, 2022	SELL	$15.46 - $20.1 $335,652 - $436,391	-21,711 Reduced 37.43%	36,300 $582,000
Q2 2022 Aug 15, 2022	BUY	$14.22 - $20.88 $614,403 - $902,162	43,207 Added 291.86%	58,011 $1.03 Million
Q1 2022 May 16, 2022	BUY	$17.2 - $22.5 $254,628 - $333,090	14,804 New	14,804 $301,000
Q1 2020 May 15, 2020	SELL	$13.89 - $25.45 $505,457 - $926,125	-36,390 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$10.7 - $22.24 $78,217 - $162,574	-7,310 Reduced 16.73%	36,390 $749,000
Q3 2019 Nov 14, 2019	SELL	$10.16 - $13.28 $112,776 - $147,408	-11,100 Reduced 20.26%	43,700 $502,000
Q2 2019 Aug 14, 2019	BUY	$10.62 - $16.59 $581,976 - $909,132	54,800 New	54,800 $721,000

254

36.9M

100K

21.1K

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.12B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.